Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.49B | 1.32B | 1.00B | 764.04M | 937.82M | 531.51M |
Gross Profit | 771.50M | 597.97M | 475.36M | 297.24M | 667.10M | 364.12M |
EBITDA | 87.02M | 89.48M | 29.91M | -320.65M | 204.26M | 139.92M |
Net Income | -2.09M | -34.13M | -58.54M | -297.50M | 124.86M | 79.48M |
Balance Sheet | ||||||
Total Assets | 1.30B | 1.19B | 1.22B | 1.29B | 1.43B | 1.07B |
Cash, Cash Equivalents and Short-Term Investments | 84.80M | 42.69M | 83.16M | 141.00M | 286.45M | 321.06M |
Total Debt | 60.02M | 713.92M | 731.58M | 744.80M | 502.72M | 311.81M |
Total Liabilities | 738.01M | 877.11M | 872.28M | 898.95M | 758.98M | 528.10M |
Stockholders Equity | 350.21M | 316.80M | 346.97M | 391.11M | 674.89M | 545.69M |
Cash Flow | ||||||
Free Cash Flow | 41.63M | 3.57M | -28.50M | -372.96M | -138.43M | -77.33M |
Operating Cash Flow | 45.81M | 15.24M | -19.38M | -338.31M | -115.44M | -61.78M |
Investing Cash Flow | -14.12M | -14.85M | -9.13M | -42.58M | -64.02M | -51.37M |
Financing Cash Flow | 16.73M | -40.86M | -29.34M | 235.43M | 97.04M | 481.45M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $924.45M | 12.01 | 8.93% | 2.69% | 7.16% | 12.20% | |
69 Neutral | $673.52M | 9.31 | 13.11% | 3.84% | 5.29% | 1200.44% | |
69 Neutral | $919.65M | 10.56 | 20.78% | ― | -1.46% | 25.24% | |
67 Neutral | $16.89B | 11.80 | 9.79% | 3.77% | 12.07% | -8.35% | |
62 Neutral | $411.08M | ― | 0.82% | ― | 20.41% | 93.09% | |
61 Neutral | $517.72M | ― | -46.84% | ― | 51.96% | 60.33% | |
48 Neutral | $428.88M | ― | -29.48% | ― | 3.76% | 16.19% |
On July 1, 2025, SelectQuote announced the passing of William T. Grant II, Vice Chairman and former President, who played a crucial role in the company’s evolution into a diversified insurance and healthcare services business. His leadership significantly impacted the company’s success and the lives of its associates. His sons, Bill and Bob Grant, will continue in their executive roles at SelectQuote.
The most recent analyst rating on (SLQT) stock is a Hold with a $2.75 price target. To see the full list of analyst forecasts on SelectQuote stock, see the SLQT Stock Forecast page.